Viemed Healthcare's biggest risks in the FY2024 10-K
- Reimbursement rate reductions and policy shifts by Medicare and Medicaid heavily dominate Viemed Healthcare's risk profile.
- Heavy reliance on third-party suppliers for medical equipment creates ongoing operational and financial exposure.
- Stringent healthcare regulations, compliance audits, and privacy laws present substantial legal and financial liabilities.
The risks most specific to Viemed Healthcare
- Risks Related to Our Industry and Business
Reductions in reimbursement rates may have a materially adverse impact on the profitability of our operations
Reductions in reimbursement rates from governmental programs like Medicare and Medicaid could materially and adversely impact our operational profitability.
- Risks Related to Our Industry and Business
Our reliance on only a few sources of reimbursement for our services could result in delays in reimbursement, which could adversely affect cash flow and revenues
Delays in reimbursement from our heavy reliance on the federal Medicare program could adversely affect our cash flow and revenues.
- Risks Related to Our Industry and Business
Our dependence on key suppliers puts us at risk of interruptions in the availability of the equipment we need for our services, which could reduce our revenue and adversely affect our results of operations
Dependence on third-party suppliers for timely equipment deliveries risks availability and pricing, which could reduce our revenue.
- Risks Relating to Government Regulation
We depend in part upon reimbursement by third-party payors
In 2024, approximately 57% of our revenues came from private pay sources and 43% from Medicare and Medicaid.
- Risks Relating to Government Regulation
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 required the HHS to establish and implement programs under which competitive acquisition areas are established throughout the United States for purposes of awarding contracts for the furnishing of competitively priced items of DME
CMS competitive acquisition programs for durable medical equipment require us to submit bids to supply covered items in designated areas.
- Risks Relating to Government Regulation
If CMS requires prior authorization for our products, our revenue and cash flow could be negatively impacted
CMS added home ventilators used with a non-invasive interface to the Master List of Items Frequently Subject to Unnecessary Utilization, risking prior authorization delays.
- Risks Relating to Government Regulation
If we fail to comply with state and federal fraud and abuse laws, including anti-kickback laws, false claims acts, self-referral prohibitions, and anti-inducement laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected
Failure to comply with federal and state fraud and abuse laws, including anti-kickback laws and false claims acts, could result in substantial penalties.
- Risks Related to our Common Shares
We no longer qualify as a “smaller reporting company” or an "emerging growth company" which may increase our costs and demands on management
We no longer qualify as a smaller reporting company or emerging growth company as of June 30, 2023, increasing our compliance costs.
All 38 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Industry and Business
- 01We compete against companies that have longer operating histories and greater resources, which may result in reduced profit margins and loss of market share
- 02Reductions in reimbursement rates may have a materially adverse impact on the profitability of our operations
- 03Our reliance on only a few sources of reimbursement for our services could result in delays in reimbursement, which could adversely affect cash flow and revenues
- 04Our dependence on key suppliers puts us at risk of interruptions in the availability of the equipment we need for our services, which could reduce our revenue and adversely affect our results of operations
- 05We conduct all of our operations through our United States subsidiaries and our ability to extract value from these subsidiaries may be limited
- 06The failure to attract or to retain management or key operating personnel, including directors, could adversely affect operations
- 07We have significant ongoing capital expenditure requirements. If we are unable to obtain necessary capital on favorable terms or at all, we may not be able to execute on our business plans and our business, financial condition, results of operations, cash flows and prospects may be adversely affected
- 08We are subject to the risks of litigation and governmental proceedings, which could adversely affect our business
- 09Insurance and claims expenses could significantly reduce our profitability
- 10We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively
- 11The integration of artificial intelligence (AI) technologies may introduce operational risks and challenges
- 12Disruptions in the credit and financial markets may have an adverse impact on our ability to obtain capital and financing for our operations
- 13Our strategic growth plan, which involves the acquisition of other businesses, may not succeed
- 14We may be negatively impacted by inflation
Risks Relating to Government Regulation
- 15Healthcare reform legislation and/or executive action may affect our business
- 16We are subject to extensive federal and state regulation, and if we fail to comply with applicable regulations, we could suffer severe criminal or civil sanctions or be required to make significant changes to our operations that could adversely affect our business, financial condition and operating results
- 17We expect the federal and state governments to continue their efforts to contain growth in Medicaid expenditures, which could adversely affect our revenue and profitability
- 18Revenue we receive from third-party payors as well as Medicare and Medicaid is subject to potential retroactive reduction
- 19As a result of increased post-payment reviews of claims we submit to Medicare and Medicaid for our services, we may incur additional costs and may be required to repay amounts already paid to us
- 20An economic downturn, state budget pressures, sustained unemployment and continued deficit spending by the federal government may result in a reduction in reimbursement and covered services
- 21Delays in reimbursement due to state budget deficits may increase in the future, adversely affecting our liquidity
- 22Delays in reimbursement due to claims submission reimbursement processes may cause liquidity problems
- 23We depend in part upon reimbursement by third-party payors
- 24We face inspections, reviews, audits and investigations under federal and state government programs and contracts. These audits could have adverse findings that may negatively affect our business
- 25We are subject to extensive federal and state laws and regulations relating to the privacy and security of protected health information and failure to comply with such laws may increase our operational costs
- 26The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 required the HHS to establish and implement programs under which competitive acquisition areas are established throughout the United States for purposes of awarding contracts for the furnishing of competitively priced items of DME
- 27If CMS requires prior authorization for our products, our revenue and cash flow could be negatively impacted
- 28If we fail to comply with state and federal fraud and abuse laws, including anti-kickback laws, false claims acts, self-referral prohibitions, and anti-inducement laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected
- 29The implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues
Risks Related to our Common Shares
- 30If we fail to establish and maintain proper disclosure or internal controls, our ability to produce accurate financial statements and supplemental information, or comply with applicable regulations could be impaired
- 31As we grow, we may be subject to growth-related risks including capacity constraints and pressure on our internal systems and controls. Our ability to manage growth effectively will require us to continue to implement and improve our operational and financial systems and to expend, train and manage our employee base
- 32The market price for our common shares may experience substantial volatility for reasons unrelated to our financial performance. This volatility may impact the price at which shareholders can sell their common shares
- 33The failure of our common shares to be included in various stock indices could result in the market for our common shares to become limited and volatile and the price at which you can sell your shares to decrease
- 34Future sales of our common shares in the public market could reduce our share price, and any additional capital raised by us through the sale of equity or convertible securities may dilute the ownership of existing shareholders
- 35We will incur increased costs as a result of operating as a U.S. public reporting company, and our management is required to devote substantial time to new compliance initiatives
- 36We no longer qualify as a “smaller reporting company” or an "emerging growth company" which may increase our costs and demands on management
- 37Because we have no current plans to pay cash dividends on our common shares, investors may not receive any return on their investment unless the value of our common shares appreciates
- 38Canadian laws differ from the laws in effect in the United States and may afford less protection to holders of our securities
Other Viemed Healthcare 10-Ks
- FY2025 10-K risk factors41 risks6 new3 dropped11 reworded
Viemed added new risks covering a CMS 6-month moratorium on medical supply enrollments and a share repurchase program.
Filed Mar 04, 2026
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.